Objectives. To describe pregnancies of women with systemic necrotizing vasculitides (SNVs), i.e. PAN, WG, ChurgStrauss syndrome (CSS) or microscopic polyangiitis (MPA), followed over the past 15 years at four French centres.
Introduction
Mean age at onset of systemic necrotizing vasculitides (SNVs), i.e. PAN, WG, ChurgStrauss syndrome (CSS) and microscopic polyangiitis (MPA), is most typically >40 years. In addition, and until recently, few women of child-bearing age with SNV could have envisaged pregnancy, because their outcomes were unsure and the most frequently used cytotoxic treatments contraindicate pregnancy for a long time and/or induce premature menopause or sterility. Hence, available review articles on pregnancy during SNV [14] are mainly based on isolated case reports and several series, each including no more than three patients [57] . We describe 12 SNV patients, with 20 pregnancies, seen during the past 15 years at four participating centres of the French Vasculitis Study Group.
Methods

Patient selection
Women diagnosed with SNV during their pregnancies or with known SNV and who subsequently became pregnant, during the past 15 years in four French Internal Medicine Departments (Cochin Hospital, Paris; Avicenne Hospital, Bobigny; Henri-Mondor Hospital, Cré teil; Bretonneau Hospital, Tours) were identified by searching patient databases, when available, and/or by asking centre physicians.
Data collection and analysis
We retrospectively analysed their main characteristics, including SNV diagnosis, clinical and biological presentations, treatment histories and outcomes before, during and after pregnancy. Disease activity and damage around conception were assessed by retrospective calculations of the BVAS [8] and Vasculitis Damage Index (VDI) [9] , respectively.
Information on pregnancy and newborn outcomes was also collected, with updates for all mothers and children before writing the article. Prematurity corresponded to delivery before the end of the 37th week of amenorrhoea. Birth weights were evaluated according to gestational age, as described by Salomon et al. [10] or Min et al. [11] for twins, and results are expressed as percentiles. Children were considered to be in good health when they had no symptoms suggestive of vasculitis or disease (other than common childhood infections) between delivery and last update, based on initial obstetricians', then pediatricians' and mothers' reports.
Results
Patient characteristics
As shown in Tables 1 and 2 , we identified 1 woman with PAN onset during the third trimester of pregnancy and 11 women who started 19 pregnancies after SNV diagnosis (8 pregnancies in the four WG patients, 6 in the three CSS patients, 2 in the one MPA patient and 1 each in two PAN and 1 cutaneous PAN patients). The MPA patient diagnosed by her treating internist had no antimyeloperoxidase antibodies and could have alternatively been classified as having cutaneous PAN. Four of these 12 women had 7 pregnancies before their vasculitis diagnosis. One of those pregnancies started 8 months before PAN onset and miscarriage occurred at 8 weeks; the others were uneventful.
SNV status around conception
For the 19 pregnancies occurring after SNV diagnosis, vasculitis diagnosis-to-pregnancy interval was 36 (4348) months, with a median age at pregnancy onset of 29 (2040) years. Six of the 11 patients had previously received CYC, with a cumulative dose of 55 g for one CSS patient. Fourteen of the 19 pregnancies began during SNV remission, with a median persistent BVAS of 3.5 (07) and VDI of 2 (04). One WG patient had just entered remission after CYC induction and had been taking AZA for 2 months before conceiving. One CSS patient had active asthma and blood eosinophilia when two of her pregnancies began. Another CSS and one PAN patients became pregnant 4 and 5 months after vasculitis diagnosis, respectively, and were treated with CSs alone or combined with AZA.
Six of these 19 pregnancies began off-treatment; 8 while on AZA, which was then stopped only for one PAN patient. One WG patient conceived under CS and CYC, leading to therapeutic abortion at 8 weeks. Another unexpected pregnancy occurred in a 39-year-old WG patient, in remission after six CYC pulses and receiving CS and rituximab (500 mg, every 6 months) for maintenance, as part of an ongoing trial. Her pregnancy, discovered at 20 weeks, was continued because no fetal abnormality was observed (normal US examination and fetal karyotype). None of the patients was taking aspirin, before or during pregnancy.
SNV status during pregnancy
Vasculitis remained quiescent or stable during 6 (30%) pregnancies (3 of which terminated in miscarriages), and some mild-or-moderate vasculitis manifestations occurred during 10 (50%). Crusting rhinitis increased during three pregnancies in three WG patients. Subglottic stenosis worsened slightly during a WG patient's pregnancies and was easily controlled after adjustment of systemic therapy (and therapeutic abortion of the fetuses conceived under CYC). Mild asthma, bronchitis, sinusitis, eosinophilia and/or paresthesias required transient prednisone (PDN) increases, up to 30 mg/day, during four pregnancies in three CSS patients. Two PAN patients had minor manifestations (arthralgias or leg pains).
The patient whose PAN appeared during pregnancy had haemoperitonitis due to rupture of pancreatic artery microaneurysms at 27 weeks. Her baby was delivered by caesarean with concomitant surgical haemostasis. Postdelivery angiography revealed hepatic, superior mesenteric and colonic artery microaneurysms. She entered remission with CS and CYC and, after six pulses, was switched to AZA.
In addition to the latter PAN patient, 3 (15%) pregnancies were severely complicated, two possibly attributable to vasculitis, despite its being in remission at their onset. The twin pregnancy of a CSS patient with heart involvement at CSS diagnosis, but ejection fraction of 53% at pregnancy onset, was complicated by sudden maternal cardiac failure at 32 weeks, leading to caesarean. The newborns were healthy and the mother recovered after 5 days of dobutamine infusion and a slight PDN increase to 20 mg/day. Rescue caesarean was also required at 32 weeks for a WG patient with impaired renal function (creatinine 150 mmol/l), resulting from the initial vasculitis flare, that further deteriorated after Week 27 with hypertension. A post-delivery kidney biopsy revealed ACEI: angiotensin-converting enzyme inhibitor; anti-PR3: anti-proteinase 3; ARDS: acute respiratory distress syndrome; B: boy; BVAS/P-BVAS/VDI: BVAS 2003 (the first number reflects recent disease activity; the second is for persistent P-BVAS, when patient has no new or recently worsening disease activity but some lingering disease manifestations; the third is vascular damage index); CS usually corresponding to 13 initial i.v. methylprednisolone pulses followed by PDN; Dx: diagnosis; Eos: blood eosinophils; FHR: fetal heart rate; G: girl; GH: good health; GI: gastrointestinal; HC: hydrocortisone; hCG: human chorionic gonadotropin; HT: hypertension; LMWH: low-molecular weight heparin; MFI: maternalfetal infection; MSAF: meconium-stained amniotic fluid; NS: non-specific; PE: plasma exchange; RCT: randomized controlled trial; Rx: treatment; VD: vaginal delivery; vWF: von Willebrand factor; VZV: varicella zoster virus; weeks: weeks of amenorrhoea.
TABLE 2
Summary of the outcomes of the 20 pregnancies in our 12 SNV patients Wegener's granulomatosis.
www.rheumatology.oxfordjournals.org thrombotic microangiopathy but no vasculitis or GN. The WG patient who received maintenance rituximab (last infusion at 12 weeks) developed community-acquired pneumonia at 37 weeks, with acute respiratory distress syndrome, necessitating a caesarean section that delivered a healthy boy. She rapidly recovered and returned home 10 days later.
Pregnancy outcomes and newborns
Six (30%) of the 20 pregnancies ended prematurely: 4 (20%) first-trimester miscarriages (1 patient each with WG, CSS, cutaneous PAN or MPA), 1 therapeutic abortion at 8 weeks (WG woman, receiving CYC) and another at 5 weeks (CSS patient, who had just completed an eventful pregnancy). The other 14 pregnancies yielded 15 liveborn infants (one dichorial diamniotic twin pregnancy). Four pregnancies (three WG and one MPA patients) were uneventful from an obstetrical perspective; 5 (33%) had premature rupture of membranes (PROM), leading to pre-term births for three of them (one patient each with WG, CSS or PAN). With the exception of the WG woman who had hypertension, renal deterioration and placenta praevia, no patient had placental abruption or pre-eclampsia. None had gestational diabetes. Seven infants were born by vaginal delivery and eight by caesarean. All had Apgar scores of 10 at 5 min. Eight (53%) were pre-term, at 32 (2737) weeks, with 6 of them having short stays (<7 days) in neonatal units, as a systematic precaution because none had immature lungs, major organ problems or maternalfetal infection. Six (40%) had birth weights 575th percentile, including four whose mothers were off CS, and four of the pre-term newborns. None of the 15 children experienced vasculitis manifestations or other systemic disease, up to the last update.
SNV status after delivery
During the six post-partum or -abortum months, no major relapses occurred. However, sinusitis or paresthesias worsened slightly in two CSS patients, ENT symptoms worsened in one WG patient, and the WG patient with severe renal deterioration during pregnancy progressed to end-stage renal disease.
Discussion
First, our results underscore that CYC exposure does not necessarily induce sterility, especially in the youngest women and when the cumulative CYC dose remained <8 g/m 2 [12] . In our study, six women had previously received CYC but conceived and delivered eight healthy children. Notably, five of those women had been prescribed continuous oral progestative drugs or a gonadotropin-releasing hormone agonist, like triptorelin, to try to preserve ovarian function when receiving CYC, as is usually done in these study centres for pre-menopausal patients. Secondly, global outcomes were good, since no mother died and all liveborn infants were healthy. SNV remained quiescent during most of the pregnancies or required only minor CS-dose adjustments. However, four (20%) mothers developed life-threatening complications during pregnancy. One was not related to SNV (infectious pneumonia) and another was the initial SNV manifestation for one patient (haemoperitonitis revealing PAN). Importantly, the two other severe complications were due to SNVrelated damage (cardiac decompensation in a CSS patient, with previous cardiac involvement; thrombotic microangiopathy caused severe renal insufficiency in a WG woman, with persistent vasculitis-related renal impairment). In addition, miscarriages were relatively frequent, as was PROM, and half the newborns were premature, for different reasons.
Our findings support and extend the results of previous reports. About 40 pregnancies have been reported in WG patients with up to 41% of them ending in pre-term deliveries [57] . When WG was in remission, complications or vasculitis flares occurred in only 25% of the pregnancies, sometimes post-partum. Conversely, outcomes were poorer when pregnancies started during active WG, with 40100% of them ending in miscarriage or therapeutic abortion or even the mother's death.
PAN becoming manifest during pregnancy often had severe manifestation and/or poor outcomes [13, 14] . When PAN was known, pregnancy was usually uneventful or marked by minor flares, mostly cutaneous [15] .
Several case reports suggested a risk of cardiac and/or asthma decompensation(s) in 2550% of pregnancies in CSS patients, mainly during the last weeks or postpartum, especially in those with known heart involvement [16, 17] , as for one of our patients. However, 6780% of the babies born to CSS mothers were healthy [16] . Data on pregnancies in MPA are scarce, but with a remarkable, though still unique, transient pulmo-renal syndrome in the newborn attributed to maternal anti-myeloperoxidase antibodies [18, 19] .
Most immunosuppressive drugs are contraindicated around conception and during pregnancy, including CYC, MTX and biologics. Conversely, AZA and CS can be used without major concern [13] , as for seven of our patients. When patients are in remission on these latter treatments around conception, it seems wiser to continue them throughout the pregnancy. One of our PAN patients stopped AZA before conception because she thought it had caused her previous miscarriage. Her pregnancy was uneventful but, in our opinion, the risk of major flare, which can require a stronger immunosuppressant, namely CYC, argues against such a potentially dangerous decision.
One of our patients, who was thought to have premature menopause after CYC, received rituximab before conception and during the first trimester of pregnancy, without obvious consequence for the newborn. However, whether rituximab can be used before or during pregnancy without harm, for both the fetus and mother, will be difficult to assess in vasculitis. Several uneventful pregnancies have been reported in rituximab-exposed women with other, more common, diseases [20] , but rituximab must be avoided in women of child-bearing age without effective contraception and/or stopped before conception, until further data are available on its safety.
Women of child-bearing age with SNV can envisage pregnancies, but must be closely and collaboratively monitored by obstetricians and vasculitis specialists [1, 2] . Conception should ideally be planned 56 months after entering remission and having stopped those immunosuppressants potentially toxic or contraindicated during pregnancy. SNV-related damage at conception appears to be a major parameter to take into account when evaluating the risk of pregnancy. A multicentre registry might be the ideal approach to further evaluate the outcomes of pregnancy in SNV patients.
Rheumatology key messages
. For SNV patients, pregnancy should ideally be planned when their disease is in remission. . Miscarriages are relatively frequent (20%), as are pre-term births (53%) and PROM (33%). . Life-threatening complications can occur (20%), especially in patients with SNV-related damage (mainly heart or kidney).
